Sign In
Buy AYLA
$0.504
+0 (+0%)
At Close: Apr 17, 2023
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor Conference
04:01pm, Wednesday, 13'th Jan 2021
REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference
08:00am, Tuesday, 05'th Jan 2021
REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
08:00am, Monday, 04'th Jan 2021
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -
Is Ayala Pharmaceuticals, Inc. (AYLA) A Good Stock To Buy?
08:15pm, Thursday, 26'th Nov 2020
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a
Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
08:01am, Tuesday, 17'th Nov 2020
- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 -
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
08:00am, Thursday, 05'th Nov 2020
REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small m
Great Escapes: Jim Salge’s Guide to New England’s Leafy Autumn Getaways
06:47pm, Friday, 09'th Oct 2020
The fall foliage expert says “leaf-peeping” is among the safest excursions during the pandemic
Ayala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
12:01pm, Thursday, 13'th Aug 2020
– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 – – On track to initiate patient dosing in Phase 2 TENACITY study of AL101 for
Is Ayala Pharmaceuticals (NASDAQ:AYLA) In A Good Position To Invest In Growth?
01:22pm, Monday, 10'th Aug 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Here's Why We're Watching Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
12:58pm, Monday, 10'th Aug 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
2020 Pipeline Insight for Gamma Secretase Inhibitors - ResearchAndMarkets.com
12:00am, Friday, 07'th Aug 2020
The
REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small m
Ayala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
12:00pm, Monday, 22'nd Jun 2020
– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds – Current cash balance expected to fund operations into second half of 2022.
Why This Ayala Pharmaceuticals Analyst Is Bullish
03:30pm, Wednesday, 10'th Jun 2020
The Phase 2 study of Ayala Pharmaceuticals Inc's (NASDAQ: AYLA) AL101 candidate is scheduled to begin in the back half of this year.Although the first data from the study could come during 2021, a saf
Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
12:01pm, Monday, 01'st Jun 2020
REHOVOT, Israel and WILMINGTON, Del., June 01, 2020 -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing.
